W
bioLLM/wiki

AI-Curated Biomedical Knowledge Base

Live
Back to List ViewGraph View

Lysosomal-associated membrane protein 3 (LAMP-3)

Overview

CD63 molecule is a member of the tetraspanin family of membrane proteins and is widely used as a canonical marker of extracellular vesicles, especially exosomes. In biomedical research, CD63 is commonly detected alongside other EV-associated proteins such as CD81, ALIX, HSP70/90, Syntenin-1, and Annexin A2 to support vesicle identity and assess preparation quality. Because it is enriched on small vesicles released by many cell types, CD63 is frequently used in exosome isolation, characterization, and capture platforms.

Functionally, CD63 is important less as a disease-specific biomarker than as a practical surface target for EV detection and enrichment. Recent studies have used CD63 aptamers, antibody-based assays, and dual-marker strategies to improve the capture of tumor-derived exosomes and other EV populations. In these settings, CD63 serves as a stable membrane handle for analytical platforms aimed at liver cancer biomarkers, colorectal cancer residual disease, spinal cord injury-related vesicles, and engineered therapeutic exosomes.

Recent Publications Summary

Recent studies involving LAMP-3 focused on exosome and extracellular vesicle platforms for cancer diagnosis, isolation, and monitoring, with LAMP-3 appearing as one of the vesicle-associated targets used in multiplex phenotyping and capture strategies. In an aptamer-engineered phenotyping system, CD63-targeted capture was combined with additional aptamers against HER2, MUC1, and PD-L1 to profile extracellular vesicle membrane proteins, supporting multiplexed and cost-effective detection of vesicle subtypes relevant to cancer diagnosis 42296185Jun. Similarly, a liposome-based exosome RNA detection platform used CD63 and PD-L1 aptamers to specifically capture tumor-derived exosomes and enable in situ RNA analysis through a regulated CRISPR/Cas12a system, illustrating how vesicle surface markers can be coupled to downstream molecular readouts for tumor progression monitoring and therapeutic efficacy evaluation 42231680Jun.

Other publications emphasized improved exosome isolation and analytical sensitivity using CD63-directed recognition. Immunomagnetic hydrogel nanofibrils functionalized with CD63-targeted aptamers were developed for rapid, high-purity exosome separation from biofluids, with faster magnetic responsivity and improved suspension stability than conventional magnetic beads 42067286May. In a dual-mode photothermal/colorimetric aptasensor, CD63-positive gastric cancer exosomes were detected using AuPt nanozymes, achieving sensitive serum readout with both colorimetric and photothermal signal enhancement 42507175Jul. A separate dual-mode self-referencing biosensing platform on a single gold nanowire used CD63 aptamer-functionalized DNA tetrahedrons for efficient capture of HepG2-derived exosomes and paired CD63-mediated capture with AFP-mediated signal tagging to improve specificity and reliability 42190059May.

Collectively, these studies show LAMP-3-associated exosomal marker workflows being used as part of broader extracellular vesicle assays rather than as a standalone therapeutic target. The reported methods relied on aptamer-based capture, nanozyme amplification, dual-mode sensing, and CRISPR/Cas12a signal transduction to improve sensitivity, specificity, and clinical utility in cancer liquid biopsy applications 42507175Jul42296185Jun42231680Jun42190059May42067286May.

⚠️ Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.